A New Era in Targeted Anti-Viral Therapeutics

Imagine coursing through the blood stream, chasing through the body, grabbing and destroying the offending virus particles. NanoViricides, Inc. is striving to bring this imagination to fruition. A nanoviricide®, as defined by the Company, is a nanomachine that is armed to destroy a particular kind of virus. Which virus? That information is programmed into the nanoviricide, akin to the postal address on an envelope.

Biomimetic Technology to “Fool” Viruses

A “nanoviricide” is an agent designed by the Company to fool a virus into attaching to this antiviral nanomachine, in the same way that the virus normally attaches to the receptors on a cell surface. Once attached, the flexible nanoviricide glob wraps around the virus and traps it. In the process, the virus also loses its coat proteins that it needs to bind to a cell. The virus is thus neutralized and effectively destroyed. A nanoviricide completes the task of dismantling the virus particle without immune system assistance. This is the putative or designed mechanism of action of a nanoviricide. Thus nanoviricides represent the next great advance in “Immunotherapeutics” (antibodies and vaccines), which are currently well established antiviral strategies.

NanoViricides, Inc. is a development stage company with this unique nanomedicine technology. The Company is developing nanotechnology-based biomimetic anti-viral medicines, that we call “nanoviricides®”.

NanoViricides, Inc. is a publicly traded company (OTC BB:Stock Symbol:NNVC)

Virus-specific nanoviricide drug candidates against five commercially important viral diseases, viz. HIV, seasonal and potentially-epidemic influenzas and bird flu, cold sores and genital herpes infection, viral eye diseases, as well as dengue viruses, have demonstrated very high levels of effectiveness in pre-clinical studies.

The Company has nominated a clinical candidate in its FluCide™ program.

Recent Nanoviricides Press Releases

December 5th, 2011 - NanoViricides, Inc Announces That It Has Submitted a Pre-IND Meeting Request to the US FDA For Its Anti-Influenza Clinical Drug Candidate, FluCide™ NanoViricides, Inc. (OTC BB: NNVC), announced today that it has submitted a pre-IND Meeting Request to the US FDA. The Company has requested an initial meeting with the US FDA to review the Company’s proposed strategy and plan for conducting safety/toxicology studies and human clinical trials required for approval of its anti-influenza clinical drug candidate, FluCide™ (i.e. NV-INF-1).			September 13th, 2011 - NanoViricides Inc. to Present at the 13th Annual Rodman & Renshaw Healthcare Conference NanoViricides, Inc. (OTC BB: NNVC), announced that its CEO, Dr. Eugene Seymour, will present at the Rodman & Renshaw Annual Global Investment Conference being held in New York City. He will discuss the nanoviricides® platform technology, the Company’s drug pipeline, its recent successes with animal studies for the Company’s influenza therapeutic FluCide™, and progress towards the initial FDA submission.
November 15th, 2011 - NanoViricides Files Quarterly Report NanoViricides, Inc. (OTC BB: NNVC), has filed its quarterly report with the Securities and Exchange Commission yesterday, November 14th, in a timely fashion.			September 6th, 2011 - NanoViricides Selects Its First FluCide™ Clinical Candidate For FDA Submission NanoViricides, Inc. (OTC BB: NNVC), announced today that it has selected a clinical candidate, now designated NV-INF-1, for FDA submission in its highly successful FluCide™ anti-influenza therapeutics program. The Company is now developing certain additional information on NV-INF-1, with input from its FDA consultants, for the pre-IND application to the FDA. The Company is planning on two separate indications for NV-INF-1: High strength dosage form for hospitalized patients with severe influenza, and a single course therapy for the out-patients with less severe influenza
November 3rd, 2011 - NanoViricides Raises an Additional $5 Million in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand NanoViricides, Inc. (OTC BB: NNVC), announced today that it has raised $5,000,000, drawing down on its previously announced universal registered shelf “Form S-3” offering. The registered shelf offering became effective on April 29, 2010 and continues to remain effective.			August 15th, 2011 - NanoViricides Reports Sustained Anti-HIV Effect with Much Shorter Drug Dosing than HAART Drug Cocktail NanoViricides, Inc. (OTC BB: NNVC.OB), reports that its lead anti-HIV candidate achieved a long term anti-HIV effect with a much shorter dosing regimen and a markedly lower total drug dose than that of the HAART Drug Cocktail therapy. Treatment with the lead anti-HIV nanoviricide reduced HIV levels and protected the human T cells (CD4+,CD8+) to the same extent as treatment with the HAART cocktail in the SCID/hu Thy/Liv mouse model. The three drug HAART cocktail used for comparison in this study is one of the combination therapies recommended for initial therapy in humans, AZT, 3TC and Efavirenz. Other specific results of this study were recently announced by the Company.
October 24th, 2011 - NanoViricides’ Anti-Virus Technology Published in Bionanotechnology II: Global Prospects NanoViricides, Inc. (OTC BB: NNVC), announced today that information about its novel, proprietary anti-virus platform technology has been published in the book Bionanotechnology II: Global Prospects. The chapter entitled “Nanoviricides - A Novel Approach to Antiviral Therapeutics” provides an in-depth presentation of the NanoViricides platform technology, evidence for how nanoviricides are believed to act plus dramatic results of nanoviricides specifically targeting certain viral diseases, such as HIV and the ocular disease, epidemic keratoconjunctivitis (EKC).			August 8th, 2011 - NanoViricides Reports That It is Financially Sound and is Progressing Towards Initial FDA Submission NanoViricides, Inc. (OTC BB: NNVC), said that it is in a financially sound position and has the resources to advance its drug pipeline through its first IND submission. The Company reported that it had more than $11.7M in cash and current assets and only approximately 0.6M in current liabilities as of July 31, 2011, based on unaudited internal financial reports. The cash in hand includes the recent raise of $2.5M from an institutional investor. The Company has neither any long term debt, nor any short term debt, other than small working capital accounts payables.
October 17th, 2011 - NanoViricides Files Annual Report - Reports Having Sufficient Funds for Current Goals NanoViricides, Inc. (OTC BB: NNVC), reports that it has filed its financial year end annual report (Form 10-K) with the Securities and Exchange Commission (SEC) on Thursday, October 13, in a timely manner. The report can be accessed at the SEC website (http://www.sec.gov/Archives/edgar/data/1379006/000114036111049401/form10k.htm.)			August 1st, 2011 - NanoViricides Expands On Prior HIVCide Effectiveness Release NanoViricides, Inc. (OTC BB: NNVC), recently reported on its completed animal study that compared its lead anti-HIV candidate HIVCide™, to a HAART (highly active anti retroviral therapy) triple drug cocktail. The cocktail used therein is based on an anti-HIV therapeutic protocol in current practice. The Company has received numerous inquiries for simplified explanation of the results.
October 4th, 2011 - NanoViricides Inc to Present at the Partnership Opportunities in Drug Delivery (PODD) Conference in Boston Today NanoViricides, Inc. (OTC BB: NNVC), announced that its President, Dr. Anil R. Diwan, will present at the “Partnership Opportunities in Drug Delivery (PODD)” Conference being held at the Omni Parker Hotel in Boston, MA, today. Dr. Diwan is invited to present in the “Track 2: Large Molecules and Biologics Delivery”.			July 27th, 2011 - NanoViricides Raises $2.5M in Shelf Offering - The Company Reports Having More than 24 Months of Cash in Hand NanoViricides, Inc. (OTC BB: NNVC), announced today that it had successfully consummated a closing with Seaside 88, LP, a Florida limited partnership (“Seaside”), on Seaside’s purchase of an additional $2.5M of the Company’s Series B Convertible Preferred Stock. With this most recent closing, Seaside has thus far funded the Company in the amount of $15,000,000.
September 26th, 2011 - NanoViricides Inc to Present at the 10th Annual NanoBusiness Conference NanoViricides, Inc. (OTC BB: NNVC), announced that its President, Dr. Anil R. Diwan, will present at the 10th Annual NanoBusiness Conference/NanoManufacturing Summit being held at the Seaport World Trade Center in Boston, MA, today. Dr. Diwan is invited to participate in the panel on “Nanomedicine and Nanodiagnostics - Innovation, Regulation and Financing.” The panel session is scheduled for 2pm to 4pm.			July 25th, 2011 - NanoViricides Reports Anti-HIV Efficacy Equivalent to HAART Drug Cocktail Treatment in Animal Study, Successfully Advancing its HIVCide Lead Optimization Program NanoViricides, Inc. (OTC BB: NNVC), reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART (highly active anti-retroviral therapy) triple drug cocktail in its recently completed animal study. Treatment with the lead anti-HIV nanoviricide reduced HIV levels and protected the human T cells (CD4+/CD8+) to the same extent as treatment with the HAART cocktail. The three drug HAART cocktail used for comparison in this study is one of the combination therapies recommended for initial therapy in humans. No evidence of drug toxicity was observed. The lead candidate will now undergo further optimization.
September 21st, 2011 - NanoViricides Inc. to Present at the French Biotech Tour - Infectious Diseases Meeting NanoViricides, Inc. (OTC BB: NNVC), announced that its President, Dr. Anil R. Diwan, will present at the French Biotech Tour Infectious Diseases Meeting being held at the MIT Faculty Club in Boston, MA, today. He will present a summary of the nanoviricides® platform technology, the Company’s drug pipeline, its recent successes with animal studies for the Company’s influenza therapeutic FluCide™, and progress towards the initial FDA submission.			July 5th, 2011 - NanoViricides Signs Consulting Agreement with BCG for FDA Submission NanoViricides, Inc. (OTC BB: NNVC), announced today that it has entered into a consulting agreement with Biologics Consulting Group, Inc. (BCG) for the preparation and submission of Investigational New Drug (IND) applications to the FDA for its nanoviricides® drug candidates against various viral diseases.
September 19th, 2011 - NanoViricides Announces Acquisition of New Space for Future Pilot cGMP Production NanoViricides, Inc. (OTC BB: NNVC), announced that Inno-Haven LLC has completed acquisition of a light industrial building. The Company anticipates that it will be leasing a portion of this space, in the near future, for laboratory facilities and cGMP production of its nanoviricides® drug candidates against various viral diseases.			June 22nd, 2011 - NanoViricides, Inc., to Present at OneMedForum NY 2011 Trans-Atlantic Conference for Emerging Healthcare and Life Science Companies NanoViricides, Inc. (OTC BB: NNVC), a company that specializes in the development and commercialization of anti-viral drugs, has been invited to present at OneMedForum New York 2011 on June 23rd-24th, 2011 at The Roosevelt Hotel in New York City (http://www.onemedplace.com/forum/presentingcompanies.php).